MedImmune Inc.

Armando Anido has served as one of our directors since July 2006 and Chief Executive Officer and President since July 2006. Since August 2003, Mr. Anido has served as a director of Adolor Corporation and currently serves as Chairman of the Governance and Nominating Committee. Mr. Anido has over 25 years of biopharmaceutical experience. Prior to Auxilium, he was the Executive Vice President, Sales and Marketing for MedImmune, Inc., a biotechnology company focused on developing and marketing products in the therapeutic areas of cancer, infectious disease and immune regulation, where he was responsible for worldwide commercialization of their portfolio. He also served on MedImmune s Executive Committee and Product Development Committee. Prior to joining MedImmune in 1999, from 1995 to 1999, Mr. Anido was with GlaxoWellcome, Inc. where he served as Vice President, Central Nervous System Marketing after joining the company as Director, HIV Marketing. Mr. Anido was employed by Lederle Labs from 1989 to 1995 in various commercial roles, culminating as Vice President, Anti-infectives. Mr. Anido received his B.S. in Pharmacy and his M.B.A. in Marketing and Finance from West Virginia University.

Dr. Frank Malinoski is MedImmune's senior vice president, medical and scientific affairs. In this role, he oversees medical and scientific activities relating to marketed products, including clinical trials and medical information. Dr. Malinoski joined MedImmune as vice president, infectious disease, medical affairs in December 2005, with responsibility for MedImmune's infectious disease and vaccines group within medical affairs. Prior to joining MedImmune, Dr. Malinoski was president of TD Consultancy, a consulting practice advising industry and government clients on vaccine development issues. Previously, he worked at Oxxon Therapeutics, Inc. as chief medical officer and executive vice president of development, and at Wyeth Pharmaceuticals, where he held positions of increasing responsibility including: vice president, global business development; vice president, medical affairs; and assistant vice president, clinical affairs. Dr. Malinoski earned his Ph.D. in microbiology from Rutgers University and his M.D. from Albany Medical College. He holds a bachelor of arts degree from Colby College in Waterville, Maine.

Dr. David Baltimore has served as a director of the Company since June 1999. He is currently President Emeritus of and Robert Andrews Millikan Professor of Biology at the California Institute of Technology, or Caltech. From October 1997 to September 2006, Dr. Baltimore was the President of Caltech. From July 1995 to October 1997, Dr. Baltimore was an Institute Professor at the Massachusetts Institute of Technology, or MIT, and from July 1994 to October 1997, the Ivan R. Cottrell Professor of Molecular Biology and Immunology at MIT. Dr. Baltimore is a director of BB Biotech, AG, a Swiss investment company. In 1975, Dr. Baltimore was the co-recipient of the Nobel Prize in Medicine.